Changes to Inflammatory Markers in Hypertensive Diabetic Patients Using an Oral Antidiabetic Medication (ROSIglitazone or Metformin or Glyburide) and an Angiotensin Receptor Blocker (TELmisartan)

Status: Completed

The purpose of the ROSITEL study is to assess the effects of Rosiglitazone, as compared to standard oral therapies for diabetes (Metformin/Sulfonylurea), on inflammatory markers and adipokine levels in diabetic patients using an angiotensin receptor blocker (ARB). We hypothesize that ARB-treated diabetic patients receiving Rosiglitazone will experience greater reductions in vascular inflammation and levels of leptin and resistin, associated with increased Adiponectin levels, compared to a Metformin/Sulfonylurea regimen, and that these benefits will result in part, from greater improvements in insulin sensitivity in the Rosiglitazone group.

Study Design: Randomized open-label, parallel group design

Intervention: Rosiglitazone vs. Metformin/Glyburide

Length of Study: 2 year

Project Start: 2006

Project Completion: Completed

# of Patients: 115

Patient Population: Type 2 DM patients either treatment naïve or on Metformin or any Sulfonylurea

PRESENTATIONS: None available


Gupta M., Teoh H., Tisgoulis M., Quan A., Braga MFB., Verma S. The effects of rosiglitazone on inflammatory biomarkers and adipokines in diabetic, hypertensive patients. Experimental and Clinical Cardiology. Winter 2012, Volume 17 Issue 4: 191-196

Presented at the Canadian Cardiovascular Congress 2010, Scientific Session

Gupta M, Teoh H, Kajil M, Tsigoulis M, Quan A, Braga M, Verma S. Rosiglitazone-based therapy reduces inflammatory biomarkers in diabetic, hypertensive patients compared to a metformin and glyburide based-regimen: The ROSITEL randomized trial. Can J Cardiol. 2010;26(Suppl D):125D

A randomized, controlled trial of the effects of rosiglitazone on adipokines, and inflammatory and fibrinolytic markers in diabetic patients: study design and protocol. Gupta M, Braga MB , Verma S. Can J Cardiol. 2008 Oct;24(10):e65-9. PMID: 18841263 [PubMed - indexed for MEDLINE]

This study was funded by CCRN through an unrestricted investigator initiated research grant from GlaxoSmithKline Canada Inc.


Learn More »


Learn More »

Learn More »


CCRN is partnering with SANSAR to provide community initiatives, implement research projects and support clinical services. Click below for more information

Learn More »